INDICATION AND EFFECT:
TauroLock™ is approved for instillation in all central venous access systems. TauroLock™ remaining in the catheter prevents the formation of a bacterial biofilm. The catheter stays infection-free.
The lock solution contains (cyclo)-taurolidine and citrate (4%). (Cyclo)-taurolidine has a broad antimicrobial activity (incl. MRSA and VRE) against gram-positive and gram-negative bacteria and fungi (e.g. Candida).
TauroLock™ is available in ampoules (single use): 3 mL and 5 mL (10 ampoules per box), and in vials (multiple use): 10 mL (100 vials per box).
TauroLock™ complies with the recommendations for the use of antimicrobial lock solutions (see Literature). We recommend TauroLock™-Hep500 for dialysis access systems.
Between dialysis sessions or in application-free periods (oncology, parenteral nutrition), TauroLock™ is instilled into the saline-rinsed access system. The filling volume of the catheter/port system should be noted in this context.
Before the next application, the lock solution is to be aspirated with a syringe and then the system is to be rinsed with saline. If it is not possible to aspirate the lock solution, TauroLock™ can be flushed out with saline. Due to the rapid degradation of (cyclo)-taurolidine, there is no systemic effect.
The use of TauroLock™ is contraindicated in patients with known citrate or (cyclo)-taurolidine allergy and in patients concurrently taking drugs that have been demonstrated to undergo undesirable interactions with citrate or (cyclo)-taurolidine.
TauroLock™ must be stored at 15 to 30°C. Ampoules are designed for single use; vials should be used up within a period of 48 hours after the first use. TauroLock™ must be neither transported nor stored under freezing conditions. Do not freeze.
This information does not supplant the Instructions for use.